Skip to contentY
Yubo International Biotech Ltd
Y
YBGJYubo International Biotech Ltd Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$12.35K$12.35Kderivedno prior Q4 2024 on file Net Income-$103.13K-$103.13KderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Yubo International Biotech Ltd · CIK 895464 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$8,165N/M Operating Incomederived-$160,564N/M Operating Cash Flowderived-$128,752N/M Margins · derivedGross margin66.1%
Operating margin-1299.8%
Net margin-834.9%
ended Dec 31, 2025 · filed Mar 31, 2026 · 90 d after period end